Peijia Medical Limited
沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

The Board of the Company is pleased to announce the unaudited condensed consolidated results of our Group for the six months ended June 30, 2025, together with the unaudited comparative figures for the six months ended June 30, 2024.

FINANCIAL HIGHLIGHTS

	Six months ended June 30,		
	2025	2024	**Period-to-period change**
	RMB'000	*RMB'000*	
	(Unaudited)	(Unaudited)	
Revenue	**353,380**	301,203	17.3%
Selling and distribution expenses	**(145,070)**	(151,565)	-4.3%
Administrative expenses	**(62,745)**	(62,625)	0.2%
Research and development expenses	**(115,636)**	(100,484)	15.1%
Segment loss	**(75,828)**	(95,809)	-20.9%
Including: segment profit of Neurointerventional Business	**40,903**	28,716	42.4%
Loss for the period	**(71,178)**	(71,283)	-0.1%

	As at June 30,	As at December 31,	
	2025	2024	**Period-to-period change**
	RMB'000	*RMB'000*	
	(Unaudited)	(Audited)	
Bank balances, cash and term deposits	**611,769**	707,775	-13.6%

BUSINESS HIGHLIGHTS

Guided by "Dedication with Passion, Devotion for Life", the Group continued to revolutionize the standard of care for valvular heart diseases and cerebrovascular diseases during the Reporting Period.

The Group generated revenue of RMB353.4 million in the Reporting Period, representing an increase of 17.3% compared to the same period in 2024. Revenue composition remained stable, with 45.7% from sales of TAVR-related products and 54.3% from sales of neurointerventional products (2024 H1: 43.3% and 56.7%, respectively). The sustainable revenue growth was primarily attributable to the robust sales growth in both the Transactheter Valve Therapeutic Business and Neurointervetional Business.

Revenue from sales of TAVR-related products in the Reporting Period increased by 24.0% period-to-period to RMB161.6 million, mainly driven by the Group's further market share gains in China's transfemoral TAVR market and a product mix shifting to newly launched premium products. During the Reporting Period, the total terminal implantation volume surpassed 2,050 units, a period-to-period increase of approximately 18.8%, once again outpacing market growth.

Revenue from sales of neurointerventional products in the Reporting Period increased 12.2% period-to-period to RMB191.8 million. The key drivers include: (i) deepening market penetration of the existing products, including DCwire® Micro Guidewire, Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilatation Catheter and (ii) the successful launch of the newly approved YonFlow® Flow Diverting Stent.

With expanded economies of scale and lean management initiatives to optimize costs and efficiency, the Group significantly improved its operational performance. The expense ratios of both segments were significantly optimized. As a result, Neurointerventional Business segment profit increased 42.4% period-to-period to RMB40.9 million, while the segment loss of the Transcatheter Valve Therapeutic Business narrowed 35.3% to RMB76.1 million. Excluding the total loss of the corresponding entities of the Future Technology Business, the Group's net loss for the period was RMB30.7 million, representing a period-to-period narrowing of 52.4%.

We relentlessly drove the widespread adoption and penetration of TAVR procedures and steadily advanced toward our goal of becoming China's foremost TAVR brand.

During the Reporting Period, we maintained our steadfast commitment to advancing TAVR technology adoption in China through comprehensive market education initiatives. Our professional sales and marketing team systematically promoted standardized techniques and innovative treatment protocols leveraging international and domestic academic conferences, the proprietary online education platform *Yijia Academy*, and offline multidimensional training programs. This integrated approach has successfully facilitated

the translation of advanced technologies into clinical practice and expanding wider access to underserved regional markets. As a result, our TAVR products were placed in over 70 new hospitals, with total coverage reaching over 720 medical institutions in China as of June 30, 2025.

Following the successive NMPA approvals of our upgraded TAVR products in 2024 — including the AV21 low-profile specification, enhanced TaurusOne®, and next-generation 3D-steerable TaurusMax™ — we now offer a comprehensive commercial TAVR portfolio encompassing TaurusOne®, TaurusElite® and TaurusMax™. This full-spectrum lineup delivers complete sizing options and tiered pricing gradients. Our stratified product portfolio maintains stable overall average ex-factory price and profit margin while expanding accessibility for diverse markets and patients. During the Reporting Period, our premium TaurusMax™ received positive clinical feedback, with physicians commending its breakthrough 3D-steering technology. We are confident that this diversified, tiered product strategy will solidify our leadership in the transfemoral TAVR marketplace.

Enhanced operational efficiency drove marked improvement in expense ratios across the Transcatheter Valve Therapeutic Business, contributing to a substantial narrowing of its segment loss by 35.3%.

Benefiting from the enhanced sales force productivity, effective expense control under the rationalization of industry competition and savings from refined operations, selling and distribution expenses for the Transcatheter Valve Therapeutic Business were RMB100.0 million, representing a period-to-period decrease of 8.3%. The segment achieved first-ever commercial profit of RMB29.1 million. With further expansion of the revenue scale, the segment selling and distribution expense ratio decreased significantly by 21.8 percentage points to 61.9%.

With the completion of three major registration clinical trials, partially offset by the accelerated progress in the HighLife® TSMVR system registration clinical trial, segment research and development expenses decreased 17.2% period-to-period to RMB54.2 million. The research and development expense ratio stood at 33.5%, a decrease of 16.7 percentage points period-to-period.

The Group-wide expense reduction initiatives implemented across all departments partially counterbalanced the higher depreciation expenses of the new headquarters building, resulting a marginal period-to-period increase of 2.8% in segment administrative expenses to RMB51.0 million. The administrative expense ratio was 31.5%, down 6.6 percentage points period-to-period.

Consequently, the segment loss narrowed substantially by 35.3% to RMB76.1 million. The Transcatheter Valve Therapeutic Business is steadily advancing towards its breakeven target.

Three core pipeline products entered the final sprint phase for registration applications; continuous breakthroughs in multiple innovative technologies solidified our industry leadership.

During the Reporting Period, we successfully completed the one-year patient follow-ups for the registration clinical trials of three pipeline products: the transfemoral AR TAVR system TaurusTrio™, the durability-enhanced AS TAVR system TaurusNXT®, and the mitral valve TEER system GeminiOne®. One-year follow-up data for all three programs have been publicly presented at major academic conferences, demonstrating excellent safety and efficacy outcomes. In May 2025, the NMPA officially accepted the registration application for TaurusTrio™. We will also submit registration applications for TaurusNXT® and GeminiOne® to the NMPA in the coming months. The three products are expected to receive registration approval sequentially between late 2025 and mid-2026. In preparation for these launches — particularly for TaurusTrio™, the AR valve with favorable competitive positioning — the Group has allocated sufficient resources to manufacturing, marketing and sales preparation, ensuring full readiness for their market launch.

Other clinical-stage products also achieved significant milestones:

HighLife® TSMVR System (Licensed-in): as of the date of this announcement, HighLife® is the most clinically advanced TMVR product in China. Leveraging global clinical data observations and early experience from its China registration clinical trial, we accelerated patient enrollment during the Reporting Period and expect to complete enrollment within 2026.

MonarQ TTVR® System (Global IP): the MonarQ TTVR® system initiated its Global Clinical Study during the Reporting Period, with the first implant successfully completed at Cedars Sinai Hospital in Los Angeles, CA, U.S. For further details, please refer to our announcement dated July 14, 2025.

ReachTactile™ robotic-assisted TAVR system (internally-developed): we completed the FIM study of ReachTactile™ with 5 patients during the Reporting Period. We will commence the registration clinical trial shortly.

The Lithotripsy Valvuloplasty System (internally-developed): the FIM study experience of applying the Lithotripsy Valvuloplasty technology in treating mitral stenosis with severe mitral annular or valvular calcification, was presented at the New York Valves Conference held in June 2025. The promising early safety and efficacy data underscore the significant potential of this platform technology in the untapped therapeutic area of mitral stenosis.

New product scaling and lean management drove sustainable business growth; the Neurointerventional Business further expanded its profit scale.

Following the achievement of full-year profitability in 2024, the Neurointerventional Business has entered a new phase of mature development. Our comprehensive product portfolio continued to demonstrate robust performance, delivering sustained revenue growth, particularly driven by DCwire® Micro Guidewire and the newly launched YonFlow® Flow Diverting Stent.

During the Reporting Period, DCwire® Micro Guidewire — commercially launched in 2024 — significantly expanded its market share through exceptional product performance, with revenue increasing nearly 140% period-to-period. In July 2024, we formally submitted and secured acceptance of its 510(k) application to the U.S. FDA, with approval anticipated by year-end 2025 to facilitate overseas expansion. Meanwhile, YonFlow® Flow Diverting Stent (exclusively distributed) obtained the NMPA registration approval in April 2025. Our marketing and sales team responded immediately with accelerated market promotion and procurement listing efforts, achieving the first commercial implant in June 2025. As of the date of this announcement, we have completed the procurement listing of YonFlow® in over 20 provinces, secured supplementary listing in the provincial alliance VBP of vascular interventional consumables led by Hebei Province, and won the bid in Guangdong Provincial VBP for Flow Diverting Stents.

Regarding VBP, both our SacSpeed® Balloon Dilatation Catheter and Fastunnel® Delivery Balloon Dilatation Catheter won bids in Group A under Rule One in the provincial alliance VBP of vascular interventional consumables led by Hebei Province in January 2025. Their competitive bid positioning resulted in substantially increased contracted volume shares compared to historical actual levels — particularly for Fastunnel® with a near fourfold growth. The implementation of this VBP is currently underway province by province. While revenue for balloon dilatation catheters encountered headwinds due to proactive ex-factory price adjustments while delayed contracted volume realization during the Reporting Period, we maintain optimism that the volume-for-price trade-off upon full implementation will alleviate these pressures in the second half of 2025. Concurrently, our coil products — among the earliest VBP-adopted neurointerventional products — have entered their renewal phase. We successfully renewed our bid in the Jiangsu Provincial VBP for coils in July 2025 and are actively preparing for renewals in other provinces.

Operationally, lean production and supply chain consolidation partially offset VBP-related revenue pressures. The segment gross margin experienced a slight decline of 1.9 percentage points to 61.8% compared to the full-year 2024. Through further optimization of sales, research and development, operations and management models — coupled with enhanced resource integration — all major expense ratios experienced period-to-period reductions. Selling and distribution expense ratio, administrative expense ratio and research and development expense ratio, decreased by 1.3, 1.7, and 5.3 percentage points period-to-period, respectively. Segment profit increased by 42.4% period-to-period to RMB40.9 million.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended June 30, 2025

		Six months ended June 30,	
	Notes	**2025**	2024
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Revenue	*5*	**353,380**	301,203
Cost of sales		**(105,757)**	(82,338)
Gross profit		**247,623**	218,865
Other income	*6*	**9,898**	9,944
Other gains and losses	*7*	**(2,394)**	1,091
Selling and distribution expenses	*8*	**(145,070)**	(151,565)
Administrative expenses	*8*	**(62,745)**	(62,625)
Research and development expenses	*8*	**(115,636)**	(100,484)
		(68,324)	(84,774)
Finance income		**5,106**	16,427
Finance costs		**(5,815)**	(132)
Finance (costs) income — net	*9*	**(709)**	16,295
Loss before tax		**(69,033)**	(68,479)
Income tax expense	*10*	**(2,145)**	(2,804)
Loss and total comprehensive expense for the period		**(71,178)**	(71,283)
Loss and total comprehensive expense for the period attributable to:			
Owners of the Company		**(69,880)**	(71,273)
Non-controlling interests		**(1,298)**	(10)
		(71,178)	(71,283)
Losses per share	*11*		
— Basic and diluted *(RMB)*		**(0.10)**	(0.10)

The above interim condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at June 30, 2025

	Note	**As at June 30, 2025** ***RMB'000*** **(Unaudited)**	As at December 31, 2024 *RMB'000* (Audited)
Non-current assets			
Property, plant and equipment		**700,531**	650,417
Right-of-use assets		**46,140**	45,339
Intangible assets		**678,383**	655,997
Financial assets at fair value through profit or loss ("**FVTPL**")		**330,666**	316,814
Term deposits		**10,000**	10,000
Other non-current assets		**7,697**	23,141
		1,773,417	1,701,708
Current assets			
Inventories		**136,980**	140,779
Trade and other receivables	*12*	**58,699**	101,038
Prepayments		**30,032**	32,659
Financial assets at FVTPL		**—**	14,745
Term deposits		**—**	31,039
Bank balances and cash		**601,769**	666,736
		827,480	986,996
Current liabilities			
Trade and other payables	*13*	**235,877**	349,563
Tax payable		**—**	1,269
Borrowings		**224,534**	89,775
Lease liabilities		**2,804**	2,090
		463,215	442,697
Net current assets		**364,265**	544,299
Total assets less current liabilities		**2,137,682**	2,246,007

	Note	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Non-current liabilities			
Deferred tax liabilities		**14,501**	16,782
Borrowings		**91,199**	158,312
Deferred income		**19,964**	20,773
Lease liabilities		**3,745**	3,221
Other payables	*13*	**22,020**	2,320
		151,429	201,408
Net assets		**1,986,253**	2,044,599
Capital and reserves			
Share capital and share premium		**6,320,410**	6,323,817
Reserves		**(4,351,365)**	(4,295,774)
Equity attributable to owners of the Company		**1,969,045**	2,028,043
Non-controlling interests		**17,208**	16,556
Total equity		**1,986,253**	2,044,599

The above interim condensed consolidated statement of financial position should be read in conjunction with the accompanying notes.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

1. GENERAL INFORMATION

Peijia Medical Limited (the "**Company**", or "**Peijia Medical**") was incorporated in the Cayman Islands on May 30, 2012 as an exempted company with limited liability under the Company Law of the Cayman Islands and its shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited. The Company and its subsidiaries (together, the "**Group**") are principally engaged in the business of research and development, manufacturing and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China (the "**PRC**") and other countries.

These condensed consolidated financial statements are presented in Renminbi ("**RMB**"), which is also the functional currency of the Company.

2. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" ("**IAS 34**") issued by the International Accounting Standards Board (the "**IASB**") as well as the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

3. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values.

Other than additional accounting policies resulting from application of amendments to IFRS Accounting Standards issued by the IASB and the application of certain accounting policies which became relevant to the Group in the current interim period, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended June 30, 2025 are the same as those presented in the Group's annual consolidated financial statements for the year ended December 31, 2024.

Application of Amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to an IFRS Accounting Standards issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2025 for the preparation of the condensed consolidated financial statements:

Amendments to IAS 21	Lack of Exchangeability

The application of the amendments to an IFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

Accounting policy newly applied by the Group

Share-based Payments

Equity-settled share-based payment transactions

Share options granted to employees

When the share options are cancelled during the vesting period, the Group accounts for the cancellation as an acceleration of vesting and therefore recognize immediately the amount that otherwise would have been recognized for services received over the remainder of the vesting period.

When the share options are forfeited (when the vesting conditions are not satisfied) after the vesting periods or cancelled, the amount previously recognized in other reserves will be transferred to accumulated losses in the Group's condensed consolidated statement of changes in equity.

4. SEGMENT

Description of segments and principal activities

The Group's business activities, for which discrete financial information is available, are regularly reviewed and evaluated by the chief operating decision-maker ("**CODM**"). The CODM, who is responsible for allocating resource and assessing performance of the operating segments, has been identified as the executive directors of the Company that make strategic decisions.

The segment results present revenue, cost of sales, selling and distribution expenses, administrative expenses, and research and development expenses of each operation segment, which is for resource allocation and performance assessment by the CODM.

Transcatheter Valve Therapeutic Business

Transcatheter Valve Therapeutic Business is primarily operated by the subsidiaries of the Company mainly comprising of Peijia Medical Technology (Suzhou) Co., Ltd. ("**Peijia Suzhou**") and Peijia Medical Technology (Shanghai) Co., Ltd. ("**Peijia Shanghai**"), which is engaged in the business of research and development, manufacturing and sales of transcatheter valve therapeutic medical devices.

Neurointerventional Business

Neurointerventional Business is primarily operated by Achieva Medical Limited together with its subsidiaries ("**Achieva Group**"), which is engaged in the business of research and development, manufacturing and sales of neurointerventional procedural medical devices.

Future Technology Business

Future Technology Business is primarily operated by the Group's dedicated technology subsidiaries, focusing on delivering globally cutting-edge therapeutic solutions for a comprehensive range of heart valve diseases. All projects target unmet clinical needs in markets lacking mature treatment options.

There were no separate segment assets and segment liabilities information provided to the CODM, as CODM does not use this information to allocate resources to or evaluate the performance of the operating segments.

The Group's operations mainly locate in the PRC. Revenue of the Group are derived from the PRC and the Group's non-current assets excluding financial assets at FVTPL are all located in the PRC.

The segment information provided to the Group's CODM for reportable segments for the relevant periods is as follows:

Segment (loss) profit

	Six months ended June 30, 2025			
	Transcatheter Valve Therapeutic Business	**Neurointerventional Business**	**Future Technology Business**	**Total**
	RMB'000	***RMB'000***	***RMB'000***	***RMB'000***
	(Unaudited)	**(Unaudited)**	**(Unaudited)**	**(Unaudited)**
Revenue	**161,606**	**191,774**	**—**	**353,380**
Cost of sales	**(32,492)**	**(73,265)**	**—**	**(105,757)**
Selling and distribution expenses	**(100,029)**	**(45,041)**	**—**	**(145,070)**
Administrative expenses	**(50,982)**	**(10,278)**	**(1,485)**	**(62,745)**
Research and development expenses	**(54,195)**	**(22,287)**	**(39,154)**	**(115,636)**
Segment (loss) profit	**(76,092)**	**40,903**	**(40,639)**	**(75,828)**

	Six months ended June 30, 2024			
	Transcatheter Valve Therapeutic Business	Neurointerventional Business	Future Technology Business	Total
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Revenue	130,317	170,886	—	301,203
Cost of sales	(23,700)	(58,638)	—	(82,338)
Selling and distribution expenses	(109,122)	(42,443)	—	(151,565)
Administrative expenses	(49,605)	(12,164)	(856)	(62,625)
Research and development expenses	(65,471)	(28,925)	(6,088)	(100,484)
Segment (loss) profit	(117,581)	28,716	(6,944)	(95,809)

Information about major customers

The major customers which contributed more than 10% of the total revenue of the Group for the six months ended June 30, 2025 and 2024 are listed as below:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Customer A	**104,292**	48,790
Customer B	**76,950**	65,922
Customer C	**73,922**	62,627
Customer D	**41,791**	N/A*

* Customer D accounted for less than 10% of the Group's total revenue for the six months ended June 30, 2024

5. REVENUE

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from sales of medical devices		
— at a point in time	**353,380**	301,203

6. OTHER INCOME

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Government grants	**6,444**	9,743
Value-added-tax extra deduction	**3,096**	201
Others	**358**	—
	9,898	9,944

7. OTHER GAINS AND LOSSES

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Net foreign exchange (loss) gain	**(3,399)**	4,660
Fair value change of financial assets at FVTPL — net	**—**	2,002
Gain (loss) on disposal of property, plant and equipment	**76**	(307)
Loss from foreign exchange forward contracts	**—**	(4,826)
Others	**929**	(438)
	(2,394)	1,091

8. EXPENSES BY NATURE

Expenses included in cost of sales, selling and distribution expenses, administrative expenses, and research and development expenses are analyzed as follows:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Change of work in process and finished goods	**2,576**	6,600
Raw materials and consumables used	**83,505**	66,798
Employee benefits expenses	**171,142**	162,235
Service expenses for research and development	**28,330**	21,467
Capitalized research and development expenses in intangible assets	**(10,665)**	—
Promotion expenses	**40,240**	31,192
Professional service fees	**34,325**	20,458
Insurance expenses	**14,038**	18,250
Travelling and transportation expenses	**8,573**	11,425
Depreciation of property, plant and equipment	**24,616**	16,538
Utilities and office expenses	**5,640**	11,705
Entertainment expenses	**5,644**	8,959
Amortization of intangible assets	**7,535**	6,786
Auditor's remuneration	**680**	2,343
Depreciation of right-of-use assets	**1,970**	1,977
Reversal of write-down of inventories	**(363)**	—
Others	**11,422**	10,279
Total cost of sales, selling and distribution expenses, administrative expenses and research and development expenses	**429,208**	397,012

9. FINANCE (COSTS) INCOME — NET

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Finance income:		
Bank interest income	**5,106**	16,427
Finance costs:		
Interests on lease liabilities	**(208)**	(132)
Interests on borrowings	**(5,607)**	(4,196)
Less: interest capitalized	**—**	4,196
Interests expenses on borrowings	**(5,607)**	—
	(5,815)	(132)
Finance income — net	**(709)**	16,295

10. INCOME TAX EXPENSE

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current tax:		
PRC Enterprise Income Tax	**(1,699)**	(2,380)
Other jurisdictions	**(2,727)**	(424)
	(4,426)	(2,804)
Deferred tax credit	**2,281**	—
	(2,145)	(2,804)

The Group's principal applicable taxes and tax rates are as follows:

1. Mainland China

The Group's PRC entities are subject to 25% or 15% (for those high-tech enterprises) tax rate pursuant to the Enterprise Income Tax Law of the PRC and the respective regulations.

According to the relevant laws and regulations promulgated by the State Administration of Taxation of the PRC that has been effective from 2023 onwards, enterprises engaging in research and development activities are entitled to claim 200% of their research and development expenses incurred as tax deductible expenses when determining their assessable profits for that period.

2. Other jurisdictions

For group entities incorporated in other jurisdictions, represent Cayman Islands, British Virgin Islands, Hong Kong and United States, no significant tax exposure was made in the condensed consolidated financial statements since no significant assessable profits generated by these group entities.

11. LOSSES PER SHARE

(a) Basic loss per share

The calculation of the basic loss per share attributable to owners of the Company is based on the following data:

	Six months ended June 30,	
	2025	2024
	(Unaudited)	(Unaudited)
Loss for the period attributable to the owners of the Company (RMB'000)	**(69,880)**	(71,273)
Weighted average number of ordinary shares for the purpose of basic loss per share (thousand)	**665,991**	679,375
Basic loss per share (RMB)	**(0.10)**	(0.10)

(b) Diluted loss per share

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. For the six months ended June 30, 2025 and 2024, the Company had one category of potential ordinary shares: the stock options granted to employees. As the Group incurred losses the six months ended June 30, 2025 and 2024, the potential ordinary shares were not included in the calculation of diluted loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the six months ended June 30, 2025 and 2024 are the same as basic loss per share.

12. TRADE AND OTHER RECEIVABLES

	As at June 30, 2025 ***RMB'000*** **(Unaudited)**	As at December 31, 2024 *RMB'000* (Audited)
Trade receivables (a)	**30,674**	22,336
Loans to employees (b)	**10,312**	11,186
Value-added tax recoverable	**15,173**	8,463
Deposits	**6,735**	4,634
Interest receivables	**1,141**	722
Other receivables	**1,533**	57,621
	65,568	104,962
Disclosed in the condensed consolidated statement of financial position as:		
— Non-current, included in other non-current assets	**6,869**	3,924
— Current	**58,699**	101,038
	65,568	104,962

(a) At June 30, 2025 and December 31, 2024, the ageing analysis of the trade receivables based on invoice date were as follows:

	As at June 30, 2025 ***RMB'000*** **(Unaudited)**	As at December 31, 2024 *RMB'000* (Audited)
Within 60 days	**30,674**	22,336

The credit period granted to the customers is usually around 60 days and the credit quality of these customers is assessed, which takes into account their available financial information, past experience and other factors.

(b) As at June 30, 2025, the Group provided loans to certain key management personnel with nominal value of Hong Kong Dollar ("**HKD**") 12,035,000 (December 31, 2024: HKD12,035,000) that were unsecured, interest-free and will be repayable from March 2026 to January 2027 (December 31, 2024: from January 2025 to March 2026).

As at June 30, 2025 and December 31, 2024, loans to key management personnel were measured at amortized cost and presented as other receivables and other non-current assets following the scheduled repayment dates.

13. TRADE AND OTHER PAYABLES

	As at June 30, 2025 ***RMB'000*** **(Unaudited)**	As at December 31, 2024 *RMB'000* (Audited)
Trade payables (a)	**38,717**	25,722
Other payables (b)	**151,973**	262,340
Other tax payables	**22,548**	13,170
Staff salaries and welfare payables	**33,958**	40,465
Liabilities arising from share-based payments with cash alternative	**10,701**	10,186
	257,897	351,883
Disclosed in the consolidated statement of financial position as:		
— Non-current liabilities, as other payables	**22,020**	2,320
— Current liabilities	**235,877**	349,563
	257,897	351,883

(a) The following is an ageing analysis of the trade payables, presented based on the invoice date, at the end of each reporting period:

	As at June 30, 2025 ***RMB'000*** **(Unaudited)**	As at December 31, 2024 *RMB'000* (Audited)
0-3 months	**28,259**	24,697
3 months to 1 year	**9,473**	547
1 year to 2 years	**985**	478
	38,717	25,722

The average credit period on purchases of goods is 30 days.

(b) During the six months ended June 30, 2025, an independent investor (the "**Investor**") entered into a share allotment agreement of a PRC-incorporated subsidiary of the Company to invest 10.72% shareholding of the subsidiary with the consideration of RMB20,000,000.

Pursuant to the agreement, group entities are obligated to repurchase the Investor's relevant shares with price of paid-in investment and 6% interest per annum, under the circumstances of (i) subsidiary's failure of initial public offering before year of 2032, (ii) the Investor's shares of the subsidiary failure to sell to other parties before year of 2032.

Management accounted for the Investor's investment on the subsidiary as non-current liability as presented in the Group's condensed consolidated statement of financial position and measured at amortized cost.

14. DIVIDEND

No dividend has been paid or declared by the Company or the companies now comprising the Group for the six months ended June 30, 2025 (six months ended June 30, 2024: nil), nor has any dividend been proposed since the end of the reporting period (six months ended June 30, 2024: nil).

MANAGEMENT DISCUSSION AND ANALYSIS

I. BUSINESS REVIEW

Overview

We have established a leading medical technology platform dedicated to addressing high-growth interventional medical device markets in China and globally. Our products and product candidates target the vast, fast-growing and under-penetrated markets with high entry barriers, including transcatheter valve therapeutic medical device market and neurointerventional procedural medical device market.

Products and Pipeline

As of the date of this announcement, our product across key business segments is as follows:

1. Transcatheter Valve Therapeutic Business: eight registered products and multiple product candidates in development.

2. Future Technology Business (a spin-off from Transcatheter Valve Therapeutic Business): three product candidates in development.

3. Neurointerventional Business: seventeen registered products and multiple product candidates in development.

The development status of our product portfolio as of the date of this announcement is summarized in the chart below:



★ Among our products, these devices are accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA.

▲ Among our products, these devices are exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (免於臨床評價醫療器械目錄) promulgated by the NMPA, as amended.

● Among our products, these devices utilized our platform technologies. For more details of the platform technologies, please see page 30.

Transcatheter Valve Therapeutic Products and Product Candidates

Our Transcatheter Valve Therapeutic Business focuses on treating the most prevalent heart valve diseases, including AS, AR, MR and TR, via transcatheter approaches.

We have a comprehensive portfolio of commercialized and pipeline products. For the Reporting Period, our revenue generated from the sales of transcatheter valve therapeutic products amounted to RMB161.6 million, representing an increase of 24.0% from approximately RMB130.3 million recorded for the six months ended June 30, 2024.

Transcatheter Aortic Valve Replacement and Repair Products and Product Candidates

TaurusOne® — First-Generation TAVR System

TaurusOne® is our internally developed first-generation TAVR product, and is designed to treat severe calcific AS using catheter-based approach. The product consists of a PAV, a delivery catheter system and a loading system. The PAV includes bovine pericardial leaflets, a nitinol frame, and a sealing skirt to prevent paravalvular leakage. Compared to porcine pericardial leaflets, bovine pericardial leaflets are generally more durable and perform better in terms of hemodynamic profile. The clinical trial of TaurusOne® was the first ever TAVR product registration clinical trial completed entirely by Chinese physicians. It is also the first domestic TAVR product whose clinical results were published in the top quartile research journal. We received the NMPA approval for the registration application of TaurusOne® in April 2021 and commercialized the product in May 2021.

In April 2024, the NMPA approved a new TaurusOne® AV21 specification, specifically designed to accommodate the smaller annulus anatomy of Chinese patients. In addition, we optimized the performance of the delivery catheter system by adding a TAV marker to enhanced visualization and adding a retrieving and repositioning function to the handle. These upgrades received NMPA approval in December 2024.

TaurusElite® — Second-Generation Retrievable TAVR System

TaurusElite® is our internally developed second-generation retrievable TAVR product. TaurusElite® has a valve design similar to that of TaurusOne® but features a key upgrade to its delivery catheter system — allowing physicians to retrieve and reposition the PAV during placement, addressing one of the key challenges. This also improves the success rate of TAVR procedures and the long-term benefits to patients, which will ultimately promote wider clinical adoption. Furthermore, the design

consists of inner and outer tubes that further enhance the pushability and flexibility of the delivery catheter system, and effectively deal with the challenges posed by the complex anatomy of the aortic arch and horizontal aorta. The TaurusElite® delivery catheter system is also available in an inline sheath model to meet the diverse needs of doctors and treat patients with complicated vascular anatomy. As of the date of this announcement, TaurusElite® remains as the record-breaking domestic retrievable TAVR product in terms of approval time.

We received the NMPA approval for the registration application of TaurusElite® in June 2021 and commercialized the product in July 2021. In April 2024, the NMPA approved a new TaurusElite® AV21 specification, specifically designed to accommodate the smaller annulus anatomy of Chinese patients.

TaurusMax™ — New Iteration Steerable TAVR System

TaurusMax™ TAVR System is an iteration of TaurusElite®. The enhanced visualization with three metal radiopaque TAV markers to identify depth, commissures and the valve alignment. Deflection catheter helps valve cross the aortic arch and the calcified leaflets easily in challenging anatomy, and improve valve coaxiality. We received the NMPA approval for the registration application of TaurusMax™ in August 2024 and commercialized the product in February 2025.

In addition to the products mentioned above, we also received the NMPA approvals for the registration application of a number of procedural accessories, including TaurusAtlas® Transfemoral Balloon Catheter, and TaurusAtlas Pro® Transfemoral Balloon Catheter, TaurusNavi® Introducer Sheath and TaurusExplora® Pre-shaped Guidewire. These are important accessories to help physicians perform the TAVR procedures using Taurus-series products.

For the Reporting Period, the sales from TaurusElite® comprised the majority of our sales of the Transcatheter Valve Therapeutic Business.

TaurusNXT® — Third-Generation Non-glutaraldehyde Crosslinked Dry-tissue TAVR System

TaurusNXT® is our internally developed third-generation TAVR system, and has significantly different tissue and structure from TaurusOne® and TaurusElite®. TaurusNXT® incorporates our patented non-glutaraldehyde bio-tissue crosslinking technology that removes the main source of valve calcification, the primary cause of prosthetic valve degeneration. The technology is expected to greatly enhance the durability and biocompatibility of the PAV. Additionally, compared to the traditional dry tissue technology using glycerin, TaurusNXT® utilizes an ultra-low temperature vacuum freeze-drying technology to maintain the physical integrity of the valve tissue

while allowing the PAV to be pre-loaded onto the delivery catheter system. The delivery catheter system of TaurusNXT® is both retrievable and steerable, making it much easier for physicians to guide the PAV to its target position, thereby further improving the safety of the procedure. As of the date of this announcement, we are preparing to submit the registration application of TaurusNXT® to the NMPA.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TaurusNXT® SUCCESSFULLY.

TaurusApex® — Polymeric Trileaflet TAVR System

TaurusApex® is our internally developed fourth-generation TAVR system featuring the polymeric trileaflet instead of biological tissue. By replacing bio-materials with high strength, stable and soft polymer materials, we are able to further improve durability and biocompatibility of the prosthetic valves. The leaflets of TaurusApex® adopt the multi-layer bionic composite braided structure which better mimics the features and hemodynamic performance of human's native valves. Polymeric trileaflet excels biological tissue in durability, tear resistance and wear resistance. As of the date of this announcement, we are conducting animal studies and associated long-term follow-up evaluation on TaurusApex®, with promising results.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TaurusApex® SUCCESSFULLY.

TaurusTrio™ — Licensed-in JenaValve Trilogy™ THV System for AR Indication

We entered into a collaboration and license agreement, a service agreement and a stock purchase agreement with JenaValve, a U.S.-based medical device company, in December 2021. Pursuant to these agreements, JenaValve has granted us an exclusive license for the Trilogy™ THV System for the treatment of symptomatic, severe AR or symptomatic, severe AS. We are entitled to develop, manufacture, and commercialize the Trilogy™ THV System in the Greater China region, and JenaValve agreed to provide services, allowing us to leverage the value of the product within the region. For further details, please refer to our announcement dated January 14, 2022.

The Trilogy™ THV System is the first commercial transfemoral TAVR system to receive CE Mark approval for the treatment of both symptomatic, severe AR and symptomatic, severe AS worldwide. The system's proprietary locator can not only anchor without calcification but also ensure valve commissure alignment. Its design, which includes supra-annular prosthesis and large-open cells, also benefits long-term hemodynamic and future percutaneous coronary intervention. Its valve inflow end

is designed with 24 high-density mesh holes to provide annular compliance and sealing. We have successfully completed the technology transfer and established local manufacturing of TaurusTrio™ TAV System in Suzhou, realizing technical consistency with Trilogy™ THV System.

On July 24, 2024, JenaValve has informed the Company that Edwards has agreed to acquire JenaValve by way of a merger (the "**Merger**"). Completion of the Merger is subject to the terms and conditions as described in the Merger agreement, including the satisfaction of customary conditions. The Merger shall not affect the Group's exclusive license with JenaValve or the Group's rights to develop and commercialize TaurusTrio™. After completion of the Merger, the Group will maintain the exclusive license to develop the THV System for AR and AS in the Greater China region. The Company believes that the Merger signifies confidence in the future prospects of treating AR with JenaValve's technology. For further details, please refer to our announcements dated July 25, 2024, July 26, 2024 and August 5, 2024.

As of the date of this announcement, the Trilogy™ THV System has been successfully implanted in several cases in Hong Kong and Taiwan, China. For TaurusTrio™, the first compassionate use treatment was conducted in Hong Kong, China, in November 2024. In mainland China, the NMPA has confirmed to accept the registration application of TaurusTrio™ in April 2025.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TaurusTrio™ SUCCESSFULLY.

Transcatheter Mitral Valve Replacement and Repair Product Candidates

HighLife® — Licensed-in TSMVR Product

In December 2020, we entered into an exclusive license agreement with HighLife SAS ("**HighLife**"), a French-based medical device company focusing on the development of a novel transseptal replacement system for treating MR. Pursuant to the agreement, we are entitled to, among other things, manufacture, develop, and commercialize the HighLife® TSMVR system in the Greater China region. Mr. Georg BÖRTLEIN, the founder of HighLife, is also the co-founder of CoreValve, Inc., a TAVR company which was acquired by Medtronic, Inc. in 2009.

The field of TMVR still faces many technical difficulties, including access to the target site, anchoring and the risk of paravalvular leakage, and LVOT obstruction. Most existing approaches are either transapical or anchoring using radial force. The HighLife® TSMVR system adopts the unique "Valve-in-Ring" concept, allowing it to self-center and self-align. This system separates the valve from its anchoring

ring and delivers the two components through the femoral artery and femoral vein, respectively, through a simple three-step procedure. The 2-component design designed for mitral valve anatomy helps to mitigate the risk of paravalvular leakage and effectively reduces catheter size. The procedure can be successfully completed using teleproctoring support. The learning curve is relatively short, evidenced by significant reduction of procedure time by the same physician.

On June 3, 2024, HighLife has received an IDE approval from the U.S. FDA to initiate a US Pivotal Study for the HighLife® TSMVR solution in the United States. On April 7, 2025, HighLife announced that it had granted U.S. FDA Breakthrough Device Designated for the HighLife® TSMVR system. As of the date of this announcement, we are carrying out the multi-center registration clinical trial for the HighLife® TSMVR system.

On July 30, 2025, our internally developed Hydrophilic Coating Guidewire — specifically designed for the critical looping step in HighLife® procedures — received registration approval from the Jiangsu Provincial Medical Products Administration. Compared to similar products on the market, this product offers superior torque control, ultrasound visibility, and length compatibility. HighLife is currently conducting import registration for the product.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET HighLife® SUCCESSFULLY.

GeminiOne® — TEER System

GeminiOne® is our internally developed TEER device, designed to treat mitral valve and tricuspid valve diseases. The product has a unique design, which enables a longer coaptation length while maintaining smaller implant size and delivery system. Other innovations include its independent leaflet grasp that reduces the complexity of the procedure, auto-locking mechanism that avoids repeated locking and unlocking during the procedure, as well as multi-angular detachment that copes with a wider range of anatomy.

As of the date of this announcement, we are preparing to submit the registration application of GeminiOne® to the NMPA. The global development of GeminiOne® is progressing in parallel. As of the date of this announcement, we have received the FDA approval for the IDE for the EFS trial of this product and also preparing for CE Mark submission.

In the meantime, we are also exploring the application of GeminiOne® TEER technology in treating tricuspid valve disease.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET GeminiOne® SUCCESSFULLY.

Sutra Hemi Valve — Transcatheter Mitral Valve Coaptation Augmentation System

In April 2021, we entered into a stock purchase agreement with Sutra Medical Inc. ("**Sutra**"), a U.S.-based medical device company that designs and develops transcatheter solutions to treat valvular heart diseases. Sutra's key product candidate, Sutra Hemi Valve, is a transcatheter mitral valve therapeutic device that adopts a hybrid approach between valve replacement and repair technology. The device is designed to treat MR using a coaptation augmentation technology that targets only the posterior mitral valve leaflet. As of the date of this announcement, Sutra is preparing for FIM study.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET Sutra Hemi Valve SUCCESSFULLY.

Future Technology Product Candidates

Our Future Technology Business was established in 2024 as a spin-off from the Transcatheter Valve Therapeutic Business. It focuses on delivering globally cutting-edge therapeutic solutions for a comprehensive range of heart valve diseases. All projects target unmet clinical needs in markets lacking mature treatment options. Currently, Future Technology Business has three product candidates, including Lithotripsy Valvuloplasty System, MonarQ TTVR® system, and ReachTactile™ robotic-assisted TAVR system. Each project is managed by an independent team and executed through dedicated subsidiaries within the Group, which maintain full autonomy in operations and financing. As of the date of this announcement, two projects have independently secured external financing.

Lithotripsy Valvuloplasty System

The Lithotripsy Valvuloplasty System (formerly named TaurusWave®) applies shockwave technology to remodel calcification on the valves. After the treatment, the mobility of the native valve is improved, leading to better hemodynamic performance. The system can be used as a stand-alone transcatheter aortic valve treatment or be used prior to TAVR, in order to alleviate valve stenosis. The FIM study for AS (10 patients) was successfully completed in the Second Affiliated Hospital Zhejiang University School of Medicine. Also, a separated entity SmartWave Medical was incorporated to further develop this platform technology for several applications and indications. FIM study for calcified mitral stenosis (10 patients) was successfully completed in Hong Kong's Prince of Wales Hospital.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET LITHOTRIPSY VALVULOPLASTY SYSTEM SUCCESSFULLY.

MonarQ TTVR® system — Acquired TTVR Product

We entered into an IP acquisition agreement, a service agreement and a stock purchase agreement with inQB8 Medical Technologies, LLC ("**inQB8**"), a U.S.-based medical technology incubator, in May 2021, to explore innovative solutions for treating structural heart diseases. The transaction includes our acquisition of a TTVR technology, namely MonarQ TTVR® system, from inQB8, and for which inQB8 will continue to develop the device in partnership with us.

The MonarQ TTVR® system is an innovative option for treating TR. Such system has a unique biodynamic attachment system that utilizes and preserves the heart's natural motion to secure the implant to the native leaflets, distribute systolic loads, and minimize paravalvular leaks over a wide range of annulus sizes.

In September 2024, we received the U.S. FDA IDE approval for EFS which serve as part of the MDR CE submission. As of the date of this announcement, the Global Clinical Study of MonarQ TTVR® system is currently underway with the first implant successfully completed in June 2025. Please refer to the announcement of the Company date July 14, 2025 for further details.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET MonarQ™ SUCCESSFULLY.

ReachTactile™ — Advancing Robotic-Assisted TAVR System

ReachTactile™, our internally developed robotic-assisted TAVR system, offers an innovative, cost-effective solution for transcatheter valve replacement or repair therapies. It targets the rapidly growing TAVR market in China and globally, addressing technical challenges during the procedure and the shortage of expert cardiologists capable to conduct a transcatheter valve replacement or repair procedure.

The mobile, modular design of ReachTactile™ fits conventional catheter rooms, allowing a single cardiologist to operate multiple devices with sub-millimeter precision. A force-sensing mechanism provides real-time tactile feedback, aiding navigation in complex vascular conditions. The Master Unit-Slave Unit architecture allows cardiologists to reduce radiation exposure and other occupational diseases. Meanwhile, remote control capabilities via ethernet enable long-distance operations and training.

As of the date of this announcement, we have completed the FIM study for ReachTactile™ and are preparing to launch the registration clinical trial.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ReachTactile™ SUCCESSFULLY.

Platform Technologies

We are committed to constantly exploring platform technologies that can be applied to a variety of therapies. As of the date of this announcement, we have three patented platform technologies, namely *Non-glutaraldehyde Crosslinked* Dry-tissue Technology, Polymeric Trileaflet Technology and Lithotripsy Valvuloplasty Technology.

Non-glutaraldehyde Crosslinked Dry-tissue Technology and Polymeric Trileaflet Technology are currently utilized in our third-generation TAVR product, TaurusNXT®, and our fourth-generation TAVR product, TaurusApex®. These technologies can also be utilized with other TAVR, TMVR or TTVR product candidates.

Lithotripsy Valvuloplasty Technology, currently utilized in the Lithotripsy Valvuloplasty System, is a non-implant solution to treat valve stenosis by remodeling the severe calcification. The technology can be applied on a stand-alone basis or as a pre-implantation step during the transcatheter valve replacement procedure. Research clinical trials utilizing this platform technology are currently underway to broaden its application.

Neurointerventional Products and Product Candidates

We have a comprehensive portfolio of registered and pipeline products that target both hemorrhagic and ischemic stroke markets. For the Reporting Period, our revenue generated from the sales of neurointerventional products amounted to RMB191.8 million, representing an increase of 12.2% from approximately RMB170.9 million for the six months ended June 30, 2024.

Hemorrhagic Products and Product Candidates

For the Reporting Period, we generated a total revenue of RMB59.9 million from hemorrhagic products, representing an increase of 8.7% from approximately RMB55.1 million for the six months ended June 30, 2024 and accounting for 31.3% of the total revenue of the Neurointerventional Business.

Detachable Coils: we have four registered detachable coil products with different detachment methods, namely, Jasper® Detachable Coil, Presgo® Detachable Coil, Jasper® SS Detachable Coil and NRcoil™ Detachable Coil. We received the NMPA approval for the registration application of Jasper® SS Detachable Coil in June 2021. The detachment process of Jasper® SS Detachable Coil is the same as that of the previous generation, Jasper® Detachable Coil, whereas Jasper® SS Detachable Coil is much softer in order to address specific clinical needs during the fill and finish processes of a cerebral aneurysm endovascular coiling procedure. We received the NMPA approval for the registration application of NRcoil™ Detachable Coil, our latest generation coil product which can be thermally detached, in August 2023. The coil is designed for framing, filling and finishing. It is a significant addition to our existing product offering of embolization coils, providing an alternative detachment method to physicians.

CereStellar™ Intracranial Adjunctive Stent: CereStellar™ Intracranial Adjunctive Stent is indicated for use with neurovascular embolization coils in the endovascular treatment of intracranial aneurysms. Stent-assisted coil embolization allows endovascular treatment of complex shaped and wide necked intracranial aneurysms. As of the date of this announcement, we are continuing to progress the patient follow-up of the multi-center registration clinical trial of CereStellar™.

YonFlow® Flow Diverting Stent: YonFlow® Flow Diverting Stent is the first retrievable stent system after complete release globally. We entered into an exclusive distribution agreement with Jiangsu NowYon Medical Limited ("**NowYon Medical**") on August 16, 2024 for selling and distributing of the YonFlow® Flow Diverting Stent in the territory of the Greater China. Please refer to the announcement of the Company dated August 28, 2024 for further details. The registration application of YonFlow® Flow Diverting Stent was approved by the NMPA in April 2025.

Ischemic Products and Product Candidates

For the Reporting Period, our revenue generated from the sales of ischemic products amounted to RMB56.8 million, representing a decrease of 3.3% from approximately RMB58.8 million for the six months ended June 30, 2023 and accounting for 29.6% of the total revenue of the Neurointerventional Business.

Products Designed for Treating AIS

Syphonet® Stent Retriever: Syphonet® Stent Retriever is an important product designed for removing thrombus in intracranial vessels in a mechanical thrombectomy procedure for patients with AIS. The product's unique design features a capture basket at the distal end, which can effectively prevent the thrombus debris from dislodging into the blood stream, thereby improving the removal of the thrombus. Additionally, the stent is designed with an optimized radial force to maintain the integrity of the lumen, even in tortuous vessels. Radiopaque wires in the stent and a radiopaque marker on the distal end allow for visualization of the entire retriever, providing physicians with better visual guidance. The Syphonet® Stent Retriever has various specifications, all compatible with 0.017-inch microcatheter. The compatibility will improve the success rate of deployment and reduce procedure time. We received the NMPA approval for the registration application of Syphonet® Stent Retriever in February 2022.

Tethys AS® Aspiration Catheter: our Tethys AS® Aspiration Catheter is specially designed for direct aspiration in mechanical thrombectomy. The 0.071-inch large lumen of the product largely increases the aspiration force, which can significantly shorten procedure time. It features a 20cm soft segment at the distal end, which conforms to the tortuous vessels and largely enhances its deliverability to the distal vessels. The optimized design of the transitional structure improves the trackability of the catheter, allowing the device to be delivered to the target vessel more easily. The entire device adopts a double-layer design with outer braids and inner coils, which allows high compressive strength and helps maintain lumen integrity. We received NMPA approval for the registration application of Tethys AS® Aspiration Catheter in May 2022.

Fluxcap® Balloon Guide Catheter: Fluxcap® Balloon Guide Catheter has 0.087-inch large lumen and is compatible with 6F intermediate catheters or aspiration catheters. The reinforced layer with transition zones leads to a balance of proximal support and distal flexibility, offering a stable passage for intracranial devices. The 0.75mm non-radiopaque segment at the tip can reduce the blind spots of the physicians and thus, improving the safety of the procedure. The compliant balloon, at its tip, can block proximal flow and effectively prevent the thrombus from dislodging into the distal vessels. We received the NMPA approval for the registration application of Fluxcap® Balloon Guide Catheter in June 2022.

With the successive launch of Syphonet® Stent Retriever, Tethys AS® Aspiration Catheter and Fluxcap® Balloon Guide Catheter, we are able to provide physicians a fully integrated solution for mechanical thrombectomy. Physicians can rely on our product combinations for different procedures, based on the clinical needs of patients.

Products Designed for Treating ICAD

SacSpeed® Balloon Dilatation Catheter: we commercially launched SacSpeed® Balloon Dilatation Catheter in the fourth quarter of 2020. The Catheter is used for dilating stenosis to help with intracranial blood supply, while treating ICAD.

Fastunnel® Delivery Balloon Dilatation Catheter: Fastunnel® Delivery Balloon Dilatation Catheter is designed for treating ICAD. As the first medical device in China which combines balloon dilatation and stent delivery in one device, its unique "zero exchange" technique redefines ICAD treatment. The product utilizes an integrated design combining the features of both balloon dilatation catheter and microcatheter, which can reduce the number of device exchanges and improve the safety of the procedure. The balloon uses Pebax® semi-compliant materials to achieve steady shape and safe expansion. Meanwhile, the stainless steel structure reinforces the entire device, and thus improves the trackability of the catheter and the deliverability of the intracranial stent system. In addition, the 150cm delivery system is compatible with intermediate catheters length of 135cm and below. We received the NMPA approval for the registration application of Fastunnel® Delivery Balloon Dilatation Catheter in May 2022.

NeuroStellar® Intracranial Stent: NeuroStellar® Intracranial Stent is designed for treating ICAD. The product is compatible with 0.017-inch microcatheter and is designed with optimized radial force which enables better stent apposition. As of the date of this announcement, we have submitted the application for the registration approval of this product to the NMPA.

Vascular Access Products and Product Candidates

For the Reporting Period, we generated a total revenue of RMB75.0 million from vascular access products, representing an increase of 32.3% from approximately RMB56.7 million for the six months ended June 30, 2024 and accounting for 39.1% of the total revenue in the Neurointerventional Business.

Tethys® Intermediate Catheter: we received the NMPA approval for the registration application of Tethys® Intermediate Catheter in October 2020. Our Tethys® Intermediate Catheter assists the delivery of diagnostic devices and/or treatment devices to the neurovascular and peripheral vascular system. It is applicable in various procedures, including aneurysm embolization, mechanical thrombectomy and ICAD procedures. The catheter provides strong support and stability for the operation of microcatheters, embolization coils, stent retrievers, and balloon dilatation catheters in distal blood vessels.

Heralder® DA Distal Access Catheter: we received the NMPA approval for the registration application of Heralder® DA Distal Access Catheter in June 2021, providing more options for the delivery of devices to different positions.

DCwire® Micro Guidewire: DCwire® Micro Guidewire is designed based on the idea of "microstructure". The term "microstructure" refers to the design of a multi-layered micro-structured device made of multiple materials through precision manufacturing. DCwire® Micro Guidewire has realized the manufacturing precision as well as the unique material properties of "microstructure", which allows the device to be precisely controlled and easy to super select vessels, enabling physicians build vascular access quickly and more easily during procedures. We received the NMPA approval for the registration application of DCwire® Micro Guidewire in June 2023. As of the date of this announcement, we have submitted and secured acceptance of the 510(k) application of this product to the U.S. FDA.

Other commercialized vascular access products include Presgo® Microcatheter, Presgo® Micro Guidewire and Heralder® Guide Catheter. Meanwhile, we are optimizing the performance of our current products by developing the next generation products based on clinical feedback and are actively advancing the development and registration for related iterative products.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP OR MARKET THE ABOVE PRODUCTS OR PRODUCT CANDIDATES SUCCESSFULLY.

Research & Development

In-house innovation and business development opportunities are crucial to the Company's R&D pipeline. Our core R&D team is led by Dr. Yi ZHANG (Chairman and chief executive officer) and Dr. Jian Fong TAN (chief technology officer). Mr. Kongrong Karl PAN retired as chief operating officer since June 2025, but transitioned to a consultant role for the Company, guiding our R&D projects. All of them are industry veterans with impressive academic and professional backgrounds, having previously worked in managerial positions at various leading players in the medical device sector.

We have extensive relationships with global leaders in both the transcatheter valve therapeutic and neurointerventional fields, including world-class scientists, physicians and industry experts. In addition to the licensing of cutting-edge technologies, we have also established overseas R&D capabilities through close collaboration:

For Sutra, the Company is the second-largest shareholder beside the founder, and has the right of first offer if Sutra proposes to offer or sell any new securities, subject to certain customary exceptions. We share R&D facilities with Sutra in the United States, and they have assisted us in expanding our R&D presence in North America. The founding team of Sutra is composed of professionals with extensive academic and industrial experience.

For inQB8, it is a medtech incubator in partnership with the Company. Under the partnership, we will have exclusive global privileges and rights to the technologies regarding the joint development of novel products and solutions in treating structural heart disease. The founding team of inQB8 has a multidisciplinary background in medtech and engineering. Before founding inQB8, the team founded CardiAQ Valve Technologies, which developed the world's first TMVR system and was later acquired by Edwards.

We have established close working relationship with world-class consultants, who provide services exclusively for us in China. They are heavily involved in our R&D process, contributing significantly to our innovative aortic, mitral and tricuspid valve products:

Dr. Nicolo PIAZZA is a renowned interventional cardiologist at McGill University Health Center and the German Heart Center in Munich. He has also served as either the chairman or a core team member in many premier transcatheter valve therapeutics conferences, including EuroPCR, PCR London Valves and PCR-CIT China Chengdu Valves. He is actively involved in our overseas business development, product promotion and clinical trials, including the clinical trial and technology transfer of HighLife® as well as the clinical trial of Lithotripsy Valvuloplasty System.

Dr. Saibal KAR joined the Company as a consultant in September 2021. He is a world-leading doctor well-known for his research and achievements in the field of structural heart therapies, particularly in mitral repair space. Dr. Saibal KAR also serves as an external consultant for various multinational medical device companies such as Medtronic plc, Boston Scientific Corporation, and Abbott Vascular Inc. He has worked as a principal investigator in several multi-center studies and randomized studies for MitraClip™. Dr. Saibal KAR is currently advising on the R&D of our mitral edge-to-edge therapies.

In 2024, we entered into a consulting agreement with Dr. Gilbert Tang, who provides us with consulting advice in the field of structural heart technology. Dr. Tang is Surgical Director of the Structural Heart Program at the Mount Sinai Health System and Professor in the Department of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai.

Suzhou SITRI Interventional Medtech Institute ("**IMI**"), an innovation incubation and investment platform dedicated to the field of vascular interventional medical devices, was established in October 2021. The IMI was proposed and funded together by the Company and with Suzhou Industrial Park Administrative Committee, Suzhou Industrial Technology Research Institute, and IMI management team. The establishment of IMI will facilitate our R&D activities by providing us with access to emerging medical device technologies that might have significant global impact, which will benefit our future business expansion.

As of June 30, 2025, we had an in-house R&D team of 169 employees dedicated to the R&D of our transcatheter valve therapeutic business, future technology business and neurointerventional business.

Intellectual Property

We remain unwavering in our commitment to independent innovation to solidify our core competitive edge. We strategically evolved the Company's IP framework from a defensive posture to a dual strategy of offense and defense in 2024. This transformation was marked by strengthened compliance in trademark usage, the establishment of a preliminary framework for trade secret management, and more comprehensive protection of our core technologies. Moreover, we obtained the GB/T 29490–2013 Intellectual Property Management System Certification in April 2022. We are currently undergoing an upgrade in accordance with the requirements of the GB/T 29490–2023 Enterprise Intellectual Property Compliance Management System, marking a significant step forward in our intellectual property management.

We have a robust intellectual property portfolio, consisting of a total of 228 granted and valid patents, 155 patents under application and 137 registered trademarks. As of June 30, 2025, there were 135 granted and valid patents, 113 patents under application and 57 registered trademarks for our Transcatheter Valve Therapeutic Business and Future Technology Business, and 93 granted and valid patents, 42 patents under application and 80 registered trademarks for our Neurointerventional Business.

Manufacturing

For our Transcatheter Valve Therapeutic Business, our new headquarters has a production area of approximately 10,000 sq.m (including functional areas such as Class 10,000 cleanroom, general workshop, warehousing workshop, quality inspection workshop, etc.), which is more than three times of the original production facilities in Zhongtian Road, Suzhou. The new plants have passed the inspection by the NMPA and obtained permission to manufacture medical devices. Currently, the annual production capacity of the new plant is about 30,000 sets, which is more than three times of the original production capacity.

For our Neurointerventional Business, we manufactured, assembled and inspected our products in an 18,843.9 sq.m self-owned property at Zhongtian Road, Suzhou, Jiangsu province. We are currently renovating and expanding our plant at Zhongtian Road, Suzhou to increase production capacity in response to the growing demand of the market. We have developed the Risk Management and Control Procedures (《風險管理控制程序》) to monitor compliance with our quality control system at every phase in a product life cycle and use scientific tools to identify, analyze, evaluate and control risks to ensure the safety and efficacy of medical devices.

We have established an advanced quality management system. It is our responsibility to develop products that allow patients to enjoy healthy lives and strictly abide by the Product Quality Law of the People's Republic of China (《中華人民共和國產品質量法》), Measures for the Supervision and Administration of Medical Device Production (《醫療器械生產監督管理辦法》), Good Manufacturing Practices for Medical Devices (《醫療器械生產質量管理規範》) and other laws and regulations. We have implemented the Non-Conforming Product Control Procedures (《不合格品控制程序》) to standardize the identification, handling, and resolution of non-compliant products throughout the entire product lifecycle — from raw material procurement and production processes to final delivery — ensuring systematic compliance and operational integrity. Our Quality Management System is aligned to relevant laws and international standards, including GMP standards and the ISO 13485:2016 Medical devices — Quality management systems.

Commercialization

The Company is committed to being physicians' most trusted product partner and service provider through three core pillars: (i) precise product positioning and superior product performance; (ii) well-rounded sales and marketing support; and (iii) end-to-end engagement across the product lifecycle.

For the Company's Transcatheter Valve Therapeutics, during the Reporting Period, we placed our products in over 70 new hospitals, expanding total coverage to approximately 720 medical institutions in China as of June 30, 2025. Total terminal implantation volume exceeded 2,050 units for the Reporting Period, representing a period-to-period growth of approximately 18.8%.

Through structured internal training programs and talent development initiatives, we have cultivated a high-performance team with industry-leading expertise in medical education and commercial operations. As of June 30, 2025, our sales and marketing workforce stood at 186 professionals, supported by a medical department of 10+ licensed physicians providing expert clinical support for patient evaluation, procedure planning, and other perioperative management affairs.

Capitalizing on continuous product iterations and the penetration of technologies into broader clinical practice, our value-driven academic initiatives have significantly enhanced commercialization efficacy. We advance the transcatheter valve therapeutic technologies through multidimensional academic ecosystem development: (i) delivering standardized procedure and core technology mastery trainings for TAVR; (ii) developing lifecycle management for AS patients based on the features of Taurus-series products; (iii) anatomical assessment and advanced techniques for the treatment of AR patients; and (iv) exchange of practical experience in complex cases and related academic and clinical hotspots. These clinician-centric academic activities have facilitated the gradual translation from iterative surgical technology to clinical treatment benefits, driving durable physician engagement and active interaction. Since its official launch in June 2022, our proprietary Yijia Institute has emerged as a leading digital education brand in the field of transcatheter valve therapy, driven by its consistent delivery of high-quality content and innovative online professional education models. The platform has attracted a total of 1,420 registered users, with clinical practitioners accounting for 84.0% of the user base. Its WeChat official account has garnered over 4,765 followers, and the cumulative readership of professional articles on the platform has exceeded 54,600 views.

During the Reporting Period, the Company's Neurointerventional Business achieved further commercial success. YonFlow® Flow Diverting Stent (exclusive distribution) obtained the NMPA registration approval in April 2025. Our marketing and sales team responded immediately with accelerated market promotion and procurement listing efforts, achieving the first commercial implant in June 2025. As of the date of this announcement, we have completed the procurement listing of YonFlow® in over 20 provinces, secured supplementary listing in the provincial alliance VBP of vascular interventional consumables led by Hebei Province, and won the bid in Guangdong Provincial VBP for Flow Diverting Stents.

As of June 30, 2025, we had 91 employees dedicated to the sales and marketing of our neurointerventional products, and our distributor network covers approximately 2,300 hospitals across 31 provinces and municipalities in China.

Facing intense market competition, we adopted differentiated marketing strategies tailored to the competitive landscape and design features of each individual product. Notably, based on the superior design and performance of our products, we have developed more than ten innovative procedure techniques that directly address unmet clinical needs and pain points, in collaboration with physicians. The promotion of these innovative techniques effectively drove the commercialization of our product portfolio during the Reporting Period, including the Syphonet® Stent Retriever (representative techniques: BASIS, COSIS), Tethys® Intermediate Catheter (representative techniques: TRUST, REST, ATTACH) and Fastunnel® Delivery Balloon Dilatation Catheter (representative techniques: Zero Exchange, FAST ICAS, ANSWER).

Since the beginning of 2023, the VBP of neurointerventional products has been progressively implemented at the provincial and regional levels. The Company has consistently and proactively engaged in relevant initiatives. Leveraging our comprehensive product portfolio, long-term brand penetration, and effective strategic pricing, we have secured winning bids multiple times, ensuring a stable supply of high-quality and cost-effective neurointerventional products to the market. Following the successful bid in the provincial alliance VBP of coils led by Jilin Province (Group A), our coil product was again selected in the 3+N Alliance VBP of coils in the Beijing-Tianjin-Hebei region in March 2024. The winning bid regions for our coil products now cover over 90% of provinces nationwide. Additionally, in the provincial alliance VBP of vascular interventional consumables led by Hebei Province in January 2025, both our SacSpeed® Balloon Dilatation Catheter and Fastunnel® Delivery Balloon Dilatation Catheter won bids in Group A under Rule One.

Future Outlook

In the future, we will remain unwavering in our mission to pioneer innovative interventional therapies for structural heart and neurovascular diseases in China and globally. Our commitment to developing and commercializing transformative solutions continues to guide our strategic direction across all business segments.

For our Transcatheter Valve Therapeutic Business, we will remain steadfast in our goal of becoming China's foremost TAVR brand. Our commercial strategy focuses on expanding market penetration in the Chinese market for our approved products — TaurusOne®, TaurusElite®, TaurusMax™ and various procedural accessories. Concurrently, we are accelerating regulatory progress for our pipeline, including TaurusTrio™, TaurusNXT® and GeminiOne®, to deliver advanced, safe and effective therapeutic options to Chinese patients. As of the date of this announcement, we have received the confirmation letter from the NMPA confirming the acceptance of the registration application for TaurusTrio™ and are preparing to submit the application for the registration approval of TaurusNXT® and GeminiOne® to the NMPA in the

coming months. We are committed to bringing them to market as quickly as we can to address significant unmet clinical needs. In addition, we will continue to invest in R&D to advance the clinical progress of our other innovative pipeline products and achieve breakthroughs.

For our Future Technology Business, we will continuously advance the financing initiatives of our subsidiaries and the R&D of cutting-edge therapeutic products to accelerate the translation of technological innovations into clinical applications, with the goal of providing high quality medical services to a greater number of patients worldwide. This strategic commitment not only benefits patients with heart valve diseases worldwide, but also enhances clinical convenience for cardiologists through technological innovation.

For our Neurointerventional Business, we will continue to maintain the momentum of revenue growth while implementing cost control measures to enhance profitability and maximize shareholder value. We will actively seize the opportunities presented through policy support and industry development, leveraging our superior product performance, outstanding sales and marketing capabilities and extensive distribution network to further expand our market share and strengthen our leading position in the industry.

II. FINANCIAL REVIEW

Revenue

For the six months ended June 30, 2025, the Group's revenue was RMB353.4 million, representing an increase of 17.3% as compared to RMB301.2 million for the six months ended June 30, 2024. Revenue from the Neurointerventional Business and Transcatheter Valve Therapeutic Business were RMB191.8 million and RMB161.6 million, representing an increase of 12.2% and 24.0% as compared to RMB170.9 million and RMB130.3 million for the six months ended 30 June 2024, respectively.

The increase in revenue was primarily attributable to: (i) further market share gains in China's TAVR market and a product mix shifting to newly launched premium products; and (ii) robust performance of key neurointerventional products, exemplified by: (a) deepening market penetration of the existing advantageous products including DCwire® Micro Guidewire, Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilatation Catheter; and (b) successful launch of the newly approved YonFlow® Flow Diverting Stent.

The following table sets forth a breakdown of our revenue generated from Neurointerventional Business for the periods indicated:

	Six months ended June 30,			
	2025		2024	
	RMB'000	***%***	*RMB'000*	*%*
Vascular Access	**74,978**	**39.1**	56,665	33.2
Ischemic	**59,920**	**31.3**	55,138	32.3
Hemorrhagic	**56,813**	**29.6**	58,763	34.3
others	**63**	**—***	320	0.2
Total	**191,774**	**100.0**	170,886	100.0

* The proportion is less than 0.1%

Cost of Sales

For the six months ended June 30, 2025, the Group's cost of sales was RMB105.8 million, representing an increase of 28.4% as compared to RMB82.3 million for the six months ended June 30, 2024. The increase was primarily attributable to the increase in the material costs, labor costs and overheads as a result of the increased sales volume of the Transcatheter Valve Therapeutic Business and Neurointerventional Business.

Gross Profit and Gross Profit Margin

As a result of the aforementioned factors, the Group's gross profit increased by 13.1%, from RMB218.9 million for the six months ended June 30, 2024 to RMB247.6 million for the six months ended June 30, 2025, in line with the increase in sales revenue. Gross profit margin is calculated as gross profit divided by revenue and multiplying the result by 100%. The Group's gross profit margin was 70.1% for the six months ended June 30, 2025, as compared to 72.7% for the six months ended June 30, 2024. The decline in gross profit margin was primarily due to headwinds caused by the VBP of neurointerventional products.

Selling and Distribution Expenses

Selling and distribution expenses decreased by 4.3% from RMB151.6 million for the six months ended June 30, 2024 to RMB145.1 million for the Reporting Period. Such decrease was primarily attributable to savings achieved through refined management in conference expenses, promotion expenses, travel costs, and other expenditures.

Administrative Expenses

Administrative expenses increased by 0.2% from RMB62.6 million for the six months ended June 30, 2024 to RMB62.7 million for the six months ended June 30, 2025. The increase was primarily driven by higher depreciation expenses, partially offset by cost control initiatives.

Research and Development Expenses

Research and development expenses increased by 15.1% from RMB100.5 million for the six months ended June 30, 2024 to RMB115.6 million for the Reporting Period. Such increase was primarily attributable to the service expenses paid for the research and development of Future Technology products.

For the Reporting Period, R&D investment in the Transcatheter Valve Therapeutic Business, Future Technology Business and Neurointerventional Business amounted to RMB54.2 million, RMB39.1 million and RMB22.3 million, respectively. The following table sets forth the components of research and development expenses for the periods indicated:

	Six months ended June 30,			
	2025		2024	
	RMB'000	***%***	*RMB'000*	*%*
Service expenses for research and development	**23,571**	**20.4**	21,467	21.4
Employee benefits expenses	**43,967**	**38.0**	43,477	43.3
Professional service fees	**17,613**	**15.2**	2,695	2.7
Raw materials and consumables used	**21,116**	**18.3**	22,527	22.4
Depreciation and amortization	**6,125**	**5.3**	5,628	5.6
Other	**3,244**	**2.8**	4,690	4.6
Total	**115,636**	**100.0**	100,484	100.0

Other gains and losses

Other gains and losses — net decreased from a net other gains of RMB1.1 million for the six months ended June 30, 2024 to a net other loss of RMB2.4 million for the six months ended June 30, 2025. This decrease was primarily due to a change in exchange gains and losses, shifting from an exchange gain of RMB4.6 million in the same period last year to an exchange loss of RMB3.4 million. Meanwhile, the Group eliminated losses on forward foreign exchange contracts, declining from RMB4.8 million in the six months ended June 30, 2024 to nil.

Finance (costs) income — net

Finance income decreased from RMB16.3 million for the six months ended June 30, 2024 to net finance costs of RMB0.7 million for the Reporting Period. The decline was primarily attributable to reduced interest income from decreased bank balances, particularly large-denomination certificates of deposit.

Gearing Ratio

Gearing ratio is calculated by dividing total liabilities by total equity and multiplying the result by 100%. As of June 30, 2025, the gearing ratio of the Group decreased to 30.9% from 31.5% as of December 31, 2024.

Net Current Assets

As of June 30, 2025, the Group's net current assets were RMB364.3 million, representing a decrease of RMB180.0 million from RMB544.3 million as of December 31, 2024. The reduction was primarily attributable to reductions in trade and other receivables and lower short-term deposit balances driven by investments in properties and plants.

Borrowings

As of June 30, 2025, the Group's borrowings which bore interest rates of 2.7%-3.6% were RMB315.7 million, as compared with RMB248.1 million as of December 31, 2024, consisting of a long-term borrowing which bore an interest rate of 3.6%-3.85%. The purpose of the long-term borrowing was for financing the construction of the new headquarter, and the purpose of the short-term borrowing was to better manage funding costs by securing more favorable interest rates.

Capital Management

The primary goal of the Group's capital management is to maintain the Group's stability and growth, safeguard its normal operations and maximize shareholders' value. The Group reviews and manages its capital structure on a regular basis. Timely adjustments are made in light of changes in operating and market conditions.

Liquidity and Financial Resources

As of June 30, 2025, the Group's total cash, cash equivalents and term deposits amounted to approximately RMB611.8 million, representing a decrease of 13.6% as compared to RMB707.8 million as of December 31, 2024. The Group continues to maintain a strong financial position and is confident that it has sufficient funds to meet its daily business operation requirements.

The Group relies on capital contributions by the shareholders as the major sources of liquidity. The Group also generates cash from sales of existing commercialized products. As the Group's business develops and expands, the Group expects to generate more net cash inflow from operating activities, by increasing sales volume of existing commercialized products and launching new products, as a result of the broader market acceptance of existing products and continued efforts in promotion and expansion, and improving cost control and operating efficiency.

The Group adopts conservative treasury policies in cash and financial management. To achieve better risk control and minimize the cost of funds, the Group's treasury is centralized. Cash is generally placed in deposits mostly denominated in U.S. Dollars, Hong Kong dollars and RMB. The Group's liquidity and financing requirements are reviewed regularly.

Capital Expenditure

For the six months ended 30 June 2025, the Group's total capital expenditure amounted to approximately RMB188.1 million, which was mainly used in (i) the continuous investment in TaurusTrio™ and TaurusNXT®; (ii) the construction of property and plant; and (iii) equipment procurement.

Significant Investment

As of June 30, 2025, the balance of non-current financial assets at FVTPL amounted to RMB330.7 million, representing nine unlisted equity investments.

inQB8

inQB8 is a medical device incubator company headquartered in Massachusetts, USA, exploring and developing new solutions for major cardiovascular diseases, including structural heart disease, type A aortic dissection, HFpEF and HFmrEF. As at June 30, 2025, we held 1,326,263 shares, representing 50% of the total equity interests of inQB8, and the fair value of the equity interests held by the Group amounted to RMB164.6 million, constituting 6.3% of our total assets as at June 30, 2025. In respect of our investment in inQB8, we had realised exchange loss of approximately RMB0.69 million during the Reporting Period.

inQB8 incubates and proceeds various start-up projects through prototype design, bench testing, and preclinical testing, allowing these early concepts to develop within inQB8 until the project is acquired or grown into an independent cardiovascular company. At present, inQB8 is in strategic cooperation with the Group to develop an innovative product for treating TR, MonarQ TTVR® system. As of the date of this announcement, the Global Clinical Study of MonarQ TTVR® system is currently underway, with the first implant successfully completed in June 2025. Based on the progress of each unlisted investee, the Company will continue to evaluate and make reasonable arrangements on the growth and development of our equity interest.

Contingent Liabilities

As of June 30, 2025, the Group did not have any significant contingent liabilities.

Material Acquisitions and Disposals

As of June 30, 2025, the Group did not have any material acquisitions and disposals of subsidiary, associates and joint ventures.

Future Plans for Material Investments or Capital Assets

As of the date of this announcement, the Group had not authorized and does not have any specific plan for any material investments or acquisitions of capital assets.

Charge on Assets

As of June 30, 2025, a land use right and property, plant and equipment of the Group with carrying amounts of RMB8.7 million and RMB346.0 million respectively have been mortgaged for a long-term bank borrowing.

Foreign Exchange Exposure

The Group has transactional currency exposures. Certain cash and cash equivalents as well as financial assets at fair value through profit or loss are dominated in foreign currencies and are exposed to foreign currency risk.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

Net proceeds from the Global Offering and the Listing on the Listing Date, and the full exercise of the Over-allotment Option, after deduction of the underwriting fees and commissions and expenses of the Company in connection with the Global Offering was approximately HK$2,587.98 million. Our Group would apply such proceeds in a manner consistent with the intended use of proceeds as disclosed in the Prospectus.

The table below sets forth the utilization of the net proceeds from the Global Offering and the expected timeline of the unutilized amount as of June 30, 2025:

Business objective as stated in the Prospectus	**Percentage to total amount** *%*	**Net proceeds** *HK$ million*	**Unutilized amount as of December 31, 2024** *HK$ million*	**Utilized amount during the Reporting Period** *HK$ million*	**Unutilized amount as of June 30, 2025** *HK$ million*	**Expected timeline for unutilized amount[1]**
Development and commercialization of our Core Product and other major product candidates	65	1,682.18	399.44	81.65	317.79	Yr 2028[2]
Ongoing pre-clinical studies and planned clinical trials, preparation for registration filings and potential commercial launches (including sales and marketing) of our other product candidates in our pipeline	10	258.80	0	0	0	—
Strengthen our research and development capabilities to enrich our product pipeline	8	207.04	30.45	18.30	12.15	Yr 2025
Expand our product portfolio or intellectual property portfolio through potential strategic acquisitions, investments, partnerships and licensing opportunities	10	258.80	0	0	0	—
Working capital and other general corporate purposes	7	181.16	0	0	0	—
Total	100	2,587.98	429.89	99.95	329.94	

Notes:

(1) The expected timeline for utilization of the unutilized net proceeds above is based on the Company's best estimation and is subject to change based on the future development of market conditions.

(2) After evaluating the Group's current R&D plans, the expected timeline for the development and commercialization of our Core Product and other major product candidates have been extended from 2025 to 2028.

As of June 30, 2025, net proceeds from the Global Offering not yet utilized were deposited with certain licensed banks in Hong Kong or the PRC.

USE OF PROCEEDS FROM THE PLACING

On January 22, 2021, the Company entered into the Placing Agreement with Morgan Stanley & Co. International plc, pursuant to which the Company appointed Morgan Stanley & Co. International plc as its placing agent to procure not less than six Placees who are Independent Third Parties to subscribe up to 33,800,000 Placing Shares at the placing price of HK$29.38 per Placing Share in accordance with the terms and conditions of the Placing Agreement. The net placing price per Placing Share after deducting related fees and expenses is approximately HK$28.74 per Share. The Placing Shares had a market value of approximately HK$1,012.31 million based on the closing price of HK$29.95 per Share as of January 21, 2021 and an aggregate nominal value of US$3,380.

The Placing Shares represented approximately 5.3% of the existing issued share capital of the Company as of the Placing Agreement date, and approximately 5.1% of the enlarged issued share capital of the Company immediately following the completion of the Placing.

The Placing was completed on January 29, 2021. An aggregate of 33,800,000 Placing Shares have been successfully placed to no less than six Placees. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, the Placees and their respective ultimate beneficial owners are professional, institutional, or other investors who are Independent Third Parties. The net proceeds from the Placing were approximately HK$971.48 million, of which the intended use was set out in the announcement of the Company dated January 22, 2021. The Placing was being undertaken to strengthen the Group's financial position and for the long term funding of its business, expansion and growth plan.

The table below sets forth the utilization of the net proceeds from the Placing and the expected timeline of the unutilized amount as of June 30, 2025:

Business objective as stated in the announcement of the Company dated January 22, 2021	**Percentage to total amount** *%*	**Net proceeds** *HK$ million*	**Unutilized amount as of December 31, 2024** *HK$ million*	**Utilized amount during the Reporting Period** *HK$ million*	**Unutilized amount as of June 30, 2025** *HK$ million*	**Expected timeline for unutilized amount[(1)]**
To fund potential product licensing and possible merger and acquisition opportunities in the area of mitral valve replacement and repair treatment, including a collaboration and license agreement for transeptal mitral valve replacement with HighLife SAS dated December 18, 2020 (for further details, please refer to the voluntary announcement of the Company, published on December 21, 2020)	30	291.44	25.31	0	25.31	Yr 2028[(2)]
To fund potential product licensing and possible merger and acquisition opportunities in other areas including tricuspid valve replacement and repair treatment	40	388.59	0	0	0	—
To fund ongoing technology transfer, product development, and research and development, across the Group	25	242.87	0	0	0	—
For other general corporate purposes	5	48.58	48.58	37.60	10.98	Yr 2025
Total	100	971.48	73.89	37.60	36.29	

Notes:

(1) The expected timeline for utilization of the unutilized net proceeds from the Placing above is based on the Company's best estimation and is subject to change based on the future development of market conditions.

(2) The Company has extended the timeline for utilizing proceeds from the Placing for the performance of the license agreement with HighLife SAS from 2025 to 2028 to align with the expected achievement of the major milestone around 2028.

As of June 30, 2025, net proceeds from the Placing not yet utilized were deposited with certain licensed banks in Hong Kong or the PRC.

HUMAN RESOURCES

As of June 30, 2025, our Group had 1,035 employees, all of whom were based in China. Our Group's total employee benefits for the Reporting Period were approximately RMB171.1 million, consisted of (i) wages, salaries and bonuses, (ii) social security costs and housing benefits, (iii) employee welfare and (iv) share-based compensation expenses.

We recruit our employees based on a number of factors, including work experience, educational background and the requirements of a relevant position. We invest in continuing education programs for our management staff and other employees to upgrade their skills and knowledge continuously. We provide our employees with regular feedback as well as internal and external training in various areas, such as product knowledge, project development and team building. We also assess our employees based on their performance to determine their salaries, promotion and career development.

In compliance with the relevant PRC labor laws, we enter into individual employment contracts with our employees covering matters such as terms, wages, bonuses, employee benefits, workplace safety, confidentiality obligations, non-competition and grounds for termination.

In addition, we are required under PRC law to make contributions to statutory employee benefit plans (including pension plans, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance and housing funds) at a certain percentage of our employees' salaries, including bonus and allowances, up to a maximum amount specified by the local government.

SUBSEQUENT EVENT AFTER THE REPORTING PERIOD

Save as disclosed in this announcement, there is no material subsequent event undertaken by the Company or by the Group after the Reporting Period and up to the date of this announcement.

INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the Reporting Period (six months ended June 30, 2024: nil).

CORPORATE GOVERNANCE PRACTICES

The Company recognizes the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted the code provisions as set out in the CG Code, as its own code to govern its corporate governance practices.

Under the code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Under the current organization structure of the Company, Dr. Zhang is the chairman of the Board and chief executive officer of the Company. With extensive experience in the medical devices industry and having served in the Company since its establishment, Dr. Zhang is in charge of overall management, business, strategic development and scientific R&D of our Group. The Board considers that vesting the roles of the chairman of the Board and the chief executive officer in the same person is beneficial to the management of our Group. The balance of power and authority is ensured by the operation of the Board, which comprises experienced and diverse individuals. The Board currently comprises three executive Directors (including Dr. Zhang), three non-executive Directors and four independent non-executive Directors, and therefore has a strong independent element in its composition.

Save as disclosed above, in the opinion of the Directors, the Company has complied with the relevant code provisions contained in the CG Code during the Reporting Period.

The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Company's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities.

Having made specific enquiries with all Directors, each of them has confirmed that he/she has complied with the Model Code during the six months ended June 30, 2025. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of our Group during the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY OR SALE OF TREASURY SHARES

From September 1, 2020, to June 30, 2025, the trustee of the RSU Scheme has purchased an aggregate of 5,859,000 Shares (representing approximately 0.8751% of the total issued share capital of the Company as of June 30, 2025) under the RSU Scheme.

Save as disclosed above, neither the Company nor any of its subsidiaries have purchased, sold or redeemed any of the Company's listed securities or sold any treasury shares (as defined under the Listing Rules) during the Reporting Period. As of June 30, 2025, the Company did not hold any treasury shares.

REVIEW OF FINANCIAL INFORMATION

Audit Committee

The Company has established an Audit Committee with written terms of reference in accordance with the Listing Rules. As of the date of this announcement, the Audit Committee comprises one non-executive Director, namely Mr. Jifeng GUAN, and three independent non-executive Directors, namely, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI. Mr. Wai Ming YIP is the chairman of the Audit Committee.

The Audit Committee has held relevant discussions with the Company's management, and reviewed the unaudited interim financial statements of the Group for the Reporting Period. The Audit Committee considered that the interim results of the Group for the Reporting Period are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

PUBLICATION OF RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the Company's website (www.peijiamedical.com). The interim report of the Company for the Reporting Period containing all the information required by the Listing Rules will be dispatched to Shareholders as per the Company's corporate communications arrangement and published on the above websites in due course.

APPRECIATION

The Board would like to thank all the colleagues for their diligence, dedication, loyalty and integrity and thank all our Shareholders, customers, bankers and other business associates for their trust and support.

DEFINITIONS

In this interim results announcement, the following expressions shall have the meanings set out below, unless the context otherwise requires:

"Achieva Group"	includes Achieva Medical and its subsidiaries
"Achieva Medical"	Achieva Medical Limited, an exempt limited liability company incorporated under the laws of the Cayman Islands on November 2, 2005, being a wholly-owned subsidiary of our Company

"AIS"	acute ischemic stroke, a disease occurs when the blood flow through the cerebral arteries is blocked by a clot (i.e., a large amount of thickened blood)
"ANSWER"	**A N**eury**S**m **W**ith stenosis treatment using fastunn**E**l delive**R**ing balloon dilatation catheter, one of our innovative techniques for neurointerventional procedures
"aortic valve"	a valve in the human heart between the left ventricle and the aorta
"AR"	aortic regurgitation
"AS"	aortic stenosis
"ATTACH"	**A T**rans-radial technique using looping **T**ethys intermediate catheter with two lo**ACH** guide wires, one of our innovative techniques for neurointerventional procedures
"Audit Committee"	the audit committee of the Board
"BASIS"	**B**alloon **A**ngiopla**S**ty with the d**I**stal protection of **S**tent retriever, one of our innovative techniques for neurointerventional procedures
"Board" or "Board of Directors"	the board of directors of the company
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China, which for the purpose of this announcement and for geographical reference only, excludes Hong Kong, Macau and Taiwan
"CODM"	chief operating decision-maker
"Company" or "our Company"	Peijia Medical Limited (沛嘉醫療有限公司), an exempt limited liability company incorporated under the laws of the Cayman Islands on May 30, 2012

"Core Product"	has the meaning ascribed thereto in Chapter 18A of the Listing Rules, which, for purposes of this announcement, refers to TaurusOne®
"COSIS"	**C**hronic artery **O**cclu**S**ion recanalization with the **I**ntracranial protection of **S**tent retriever, one of our innovative techniques for neurointerventional procedures
"delivery catheter system"	an integral delivery catheter with a tip, a sheath tube, a catheter and a handle system used to deliver and release the PAV to the target position
"Director(s)"	the director(s) of the Company
"Dr. Zhang"	Dr. Yi ZHANG, one of our Founders, and our chairman, chief executive officer, an executive Director of our Company and our substantial shareholder upon Listing
"EFS"	Early Feasibility Study, an FDA Early Feasibility Study is a structured, exploratory clinical investigation performed under an IDE that enables the early clinical evaluation of a medical device in a small cohort of human subjects. It is designed to generate preliminary safety and functional data, refine device design or procedural methodologies, and assess the feasibility of advancing the device to more comprehensive clinical trials. These studies are particularly critical for novel devices with limited predicate data, allowing developers to address uncertainties and mitigate risks early in the regulatory pathway
"FDA"	U.S. Food and Drug Administration
"FIM"	First-in-man, a stage of clinical trial
"FAST ICAS"	**FAST**unnel in thrombectomy for **ICAS** occlusion, one of our innovative techniques for neurointerventional procedures
"Global Offering"	has the meaning as ascribed to it under the Prospectus

"Group," "our Group," "our," "we," or "us"	our Company and all of its subsidiaries (including but not limited to Achieva Group), or any one of them as the context may require or, where the context refers to any time prior to its incorporation or the Share Swap, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollars", "HKD" or "HK$"	Hong Kong dollars and cents, respectively, the lawful currency of Hong Kong
"ICAD"	intracranial atherosclerotic disease, a disease occurs when plaque (cholesterol, fatty deposits and other materials) builds up in the blood vessels at the base of the brain, causing them to narrow and harden
"ICAS"	intracranial atherosclerosis-related large vascular occlusion
"IDE"	Investigational Device Exemption, a regulatory authorization from the FDA that permits the use of an unapproved medical device in a clinical study. It allows researchers to collect safety and effectiveness data on the device in human subjects, typically required for significant-risk device investigations before pursuing market approval
"IFRS"	International Financial Reporting Standards, as issued from time to time by the International Accounting Standards Board
"Independent Third Party" or "Independent Third Parties"	a person or entity who is not a connected person of our Company under the Listing Rules
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange

"Listing Date"	the date, Friday, May 15, 2020, on which the Shares were listed and dealings in the Shares first commence on the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended, supplemented or otherwise modified from time to time)
"LVOT"	left ventricular outflow tract, the anatomic structure through which the left ventricular stroke volume passes towards the aorta
"MDR"	a new set of regulations that govern the clinical investigation, production and distribution of medical devices in Europe
"mechanical thrombectomy"	a type of minimally-invasive therapy in which blood clot is removed from arteries using imaging techniques guiding medical devices through patients' arteries to the blood clot
"microstructure"	the design of a multi-layered micro-structured device made of multiple materials through precision manufacturing
"mitral valve"	the valve that lets blood flow from one chamber of the heart, the left atrium, to another called the left ventricle
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"MR"	mitral regurgitation
"Neurointerventional Business"	the business of our Group in research and development of neurointerventional procedural medical devices
"neurointerventional procedural medical devices"	medical devices for treatment of neurovascular diseases using interventional endovascular technique
"neurovascular diseases"	also known as cerebrovascular diseases, including any abnormality of the blood vessels within the brain and spine or abnormality with supplying blood to such areas

"NMPA"	the National Medical Products Administration of the PRC (國家藥品監督管理局), formerly known as the China Food and Drug Administration or the CFDA
"Over-allotment Option"	has the meaning as ascribed to it under the Prospectus
"PAV"	prosthetic aortic valve, the artificial valve of our TAVR Products
"Peijia Shanghai"	Peijia Medical Technology (Shanghai) Co., Ltd. (沛嘉醫療科技(上海)有限公司), a limited liability company incorporated under the laws of PRC on February 24, 2012, being an indirect wholly-owned subsidiary of our Company
"Peijia Suzhou"	Peijia Medical Technology (Suzhou) Co., Ltd. (沛嘉醫療科技(蘇州)有限公司), a limited liability company incorporated under the laws of PRC on March 4, 2013, being an indirect wholly-owned subsidiary of our Company
"Placee(s)"	any individuals, corporate, institutional or other investor(s) procured by the Placing Agent or their respective agents to subscribe for any of the Placing Shares pursuant to the Placing Agreement
"Placing"	the placing of 33,800,000 Placing Shares pursuant to the terms of the Placing Agreement
"Placing Agreement"	the conditional placing agreement entered into between the Company and Morgan Stanley & Co. International plc dated January 22, 2021 in relation to the Placing
"Prospectus"	the prospectus of the Company dated May 5, 2020, in relation to the Global Offering
"Reporting Period"	the six months ended June 30, 2025

"REST"	**T**rans-**R**adial **E**stablish **S**imple access technique with **T**ethys intermediate catheter, one of our innovative techniques for neurointerventional procedures
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"RSU Scheme"	the restricted share unit award scheme of the Company conditionally approved and adopted by our Shareholders on April 28, 2020, the principal terms of which are set out in Prospectus
"R&D"	research and development
"Share(s)"	ordinary share(s) with nominal value of US$0.0001 each in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"SmartWave Medical"	SmartWave Medical (Changzhou) Co., Ltd. (智維心醫療科技(常州)有限公司), a limited liability company incorporated under the laws of PRC on May 27, 2024, being a subsidiary of our Company
"sq.m."	square meter, a unit of area
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary"	has the meaning ascribed thereto under the Listing Rules
"TAVR"	transcatheter aortic valve replacement, a catheter-based technique to implant a new aortic valve in an interventional procedure that does not involve open-chest surgery
"TEER"	transcatheter edge-to-edge repair
"TMVR"	transcatheter mitral valve replacement, a catheter-based technique to implant a new mitral valve in an interventional procedure that does not involve open-chest surgery

"Transcatheter Valve Therapeutic Business"	the business of our Group in research and development of transcatheter valve therapeutic medical devices
"transcatheter valve therapeutic medical devices"	medical devices for the treatment of valvular heart diseases using cardiovascular interventional technique by implanting a prosthetic valve through an artery
"TR"	tricuspid regurgitation
"tricuspid valve"	the valve on the right dorsal side of the mammalian heart, between the right atrium and the right ventricle, the function of which is to prevent back flow of blood from the right ventricle into the right atriums
"TRUST"	**T**rans-**R**adial coaxial catheter technique **U**sing a short sheath, **S**immons catheter and **T**ethys intermediate catheter, one of our innovative techniques for neurointerventional procedures
"TSMVR"	transseptal mitral value replacement, a catheter-based technique to implant a new mitral valve in an interventional procedure that does not involve open-chest surgery through transseptal puncture approach
"TTVR"	transcatheter tricuspid valve replacement, a catheter-based technique to implant a new tricuspid valve in an interventional procedure that does not involve open-chest surgery
"United States" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"U.S. dollars", "US$" or "USD"	United States dollars, the lawful currency of the United States
"valvular heart diseases"	the failure or dysfunction of one or more of the four heart valves, where the valves become too narrow and hardened to open fully, or are unable to close completely
"valvuloplasty"	a procedure using balloons to repair a heart valve with a narrowed opening and to improve blood flow through the valve

"VBP" or "volume-based procurement"	a program that enables local governments to procure medical devices in high volume and at low cost, thereby driving down medical expenses for patients
"Zhicheng Medical"	Zhicheng Medical (Jiaxing) Co., Ltd. (智程醫療科技(嘉興)有限公司), a limited liability company incorporated under the laws of PRC on May 31, 2023, being a subsidiary of our Company
"%"	per cent

By order of the Board
Peijia Medical Limited
Dr. Yi ZHANG
Chairman and Executive Director

Hong Kong, August 22, 2025

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.